Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations
Asthma exacerbations are frightening for patients and are occasionally fatal. We tested the concept that a plan for patients to manage their asthma (self-management plan), which included a temporary quadrupling of the dose of inhaled glucocorticoids when asthma control started to deteriorate, would...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2018
|
| _version_ | 1797097421671497728 |
|---|---|
| author | McKeever, T Mortimer, K Wilson, A Walker, S Brightling, C Skeggs, A Pavord, I Price, D Duley, L Thomas, M Bradshaw, L Higgins, B Haydock, R Mitchell, E Devereux, G Harrison, T |
| author_facet | McKeever, T Mortimer, K Wilson, A Walker, S Brightling, C Skeggs, A Pavord, I Price, D Duley, L Thomas, M Bradshaw, L Higgins, B Haydock, R Mitchell, E Devereux, G Harrison, T |
| author_sort | McKeever, T |
| collection | OXFORD |
| description | Asthma exacerbations are frightening for patients and are occasionally fatal. We tested the concept that a plan for patients to manage their asthma (self-management plan), which included a temporary quadrupling of the dose of inhaled glucocorticoids when asthma control started to deteriorate, would reduce the incidence of severe asthma exacerbations among adults and adolescents with asthma.We conducted a pragmatic, unblinded, randomized trial involving adults and adolescents with asthma who were receiving inhaled glucocorticoids, with or without add-on therapy, and who had had at least one exacerbation in the previous 12 months. We compared a self-management plan that included an increase in the dose of inhaled glucocorticoids by a factor of 4 (quadrupling group) with the same plan without such an increase (non-quadrupling group), over a period of 12 months. The primary outcome was the time to a first severe asthma exacerbation, defined as treatment with systemic glucocorticoids or an unscheduled health care consultation for asthma.A total of 1922 participants underwent randomization, of whom 1871 were included in the primary analysis. The number of participants who had a severe asthma exacerbation in the year after randomization was 420 (45%) in the quadrupling group as compared with 484 (52%) in the non-quadrupling group, with an adjusted hazard ratio for the time to a first severe exacerbation of 0.81 (95% confidence interval, 0.71 to 0.92; P=0.002). The rate of adverse effects, which were related primarily to local effects of inhaled glucocorticoids, was higher in the quadrupling group than in the non-quadrupling group.In this trial involving adults and adolescents with asthma, a personalized self-management plan that included a temporary quadrupling of the dose of inhaled glucocorticoids when asthma control started to deteriorate resulted in fewer severe asthma exacerbations than a plan in which the dose was not increased. (Funded by the Health Technology Assessment Programme of the National Institute for Health Research; Current Controlled Trials number, ISRCTN15441965 .). |
| first_indexed | 2024-03-07T04:55:16Z |
| format | Journal article |
| id | oxford-uuid:d661df12-1779-400a-9741-e114d7baf301 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:55:16Z |
| publishDate | 2018 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:d661df12-1779-400a-9741-e114d7baf3012022-03-27T08:33:05ZQuadrupling inhaled glucocorticoid dose to abort asthma exacerbationsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d661df12-1779-400a-9741-e114d7baf301EnglishSymplectic Elements at OxfordMassachusetts Medical Society2018McKeever, TMortimer, KWilson, AWalker, SBrightling, CSkeggs, APavord, IPrice, DDuley, LThomas, MBradshaw, LHiggins, BHaydock, RMitchell, EDevereux, GHarrison, TAsthma exacerbations are frightening for patients and are occasionally fatal. We tested the concept that a plan for patients to manage their asthma (self-management plan), which included a temporary quadrupling of the dose of inhaled glucocorticoids when asthma control started to deteriorate, would reduce the incidence of severe asthma exacerbations among adults and adolescents with asthma.We conducted a pragmatic, unblinded, randomized trial involving adults and adolescents with asthma who were receiving inhaled glucocorticoids, with or without add-on therapy, and who had had at least one exacerbation in the previous 12 months. We compared a self-management plan that included an increase in the dose of inhaled glucocorticoids by a factor of 4 (quadrupling group) with the same plan without such an increase (non-quadrupling group), over a period of 12 months. The primary outcome was the time to a first severe asthma exacerbation, defined as treatment with systemic glucocorticoids or an unscheduled health care consultation for asthma.A total of 1922 participants underwent randomization, of whom 1871 were included in the primary analysis. The number of participants who had a severe asthma exacerbation in the year after randomization was 420 (45%) in the quadrupling group as compared with 484 (52%) in the non-quadrupling group, with an adjusted hazard ratio for the time to a first severe exacerbation of 0.81 (95% confidence interval, 0.71 to 0.92; P=0.002). The rate of adverse effects, which were related primarily to local effects of inhaled glucocorticoids, was higher in the quadrupling group than in the non-quadrupling group.In this trial involving adults and adolescents with asthma, a personalized self-management plan that included a temporary quadrupling of the dose of inhaled glucocorticoids when asthma control started to deteriorate resulted in fewer severe asthma exacerbations than a plan in which the dose was not increased. (Funded by the Health Technology Assessment Programme of the National Institute for Health Research; Current Controlled Trials number, ISRCTN15441965 .). |
| spellingShingle | McKeever, T Mortimer, K Wilson, A Walker, S Brightling, C Skeggs, A Pavord, I Price, D Duley, L Thomas, M Bradshaw, L Higgins, B Haydock, R Mitchell, E Devereux, G Harrison, T Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations |
| title | Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations |
| title_full | Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations |
| title_fullStr | Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations |
| title_full_unstemmed | Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations |
| title_short | Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations |
| title_sort | quadrupling inhaled glucocorticoid dose to abort asthma exacerbations |
| work_keys_str_mv | AT mckeevert quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT mortimerk quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT wilsona quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT walkers quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT brightlingc quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT skeggsa quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT pavordi quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT priced quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT duleyl quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT thomasm quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT bradshawl quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT higginsb quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT haydockr quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT mitchelle quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT devereuxg quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations AT harrisont quadruplinginhaledglucocorticoiddosetoabortasthmaexacerbations |